Meeting
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
Authors
Yuming Zhu
Department of Medical Oncology,Shanghai Pulmonary Hospital, Shanghai, China
Yuming Zhu , Tao Jiang , Lianghua Fang , Tao Zhang , Xiaoyan Kang , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT05487391
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8606)
DOI
10.1200/JCO.2023.41.16_suppl.TPS8606
Abstract #
TPS8606
Poster Bd #
229b
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC.
First Author: Howard Jack West
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino
Poster
2016 ASCO Annual Meeting
Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
First Author: Martin Reck